Tarsus Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Tarsus Pharmaceuticals, Inc. (TARS) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-115.55-135.89-62.09-13.83-26.81
Depreciation & Amortization1.231.26-0.220.610.10
Stock Based Compensation27.8219.8313.468.460.84
Change in Working Capital3.84-7.42-3.67-0.391.46
Change in Accounts Receivable-30.14-16.620.000.000.02
Change in Inventory-2.05-3.110.000.000.00
Change in Accounts Payable40.3413.240.823.883.24
Change in Other Working Capital-4.310.93-1.77-2.51-1.80
Other Operating Activities-0.3617.2113.7314.543.28
Net Cash from Operating Activities-83.03-117.49-49.033.75-21.14
Investing Activities
Capital Expenditures-1.57-5.500.510.59-0.46
Purchases of Investments-265.63-28.66-144.120.000.00
Sales/Maturities of Investments73.00174.77-144.120.000.00
Other Investing Activities-5.000.000.000.000.00
Net Cash from Investing Activities-199.20140.60-144.63-0.59-0.46
Financing Activities
Debt Repayment39.600.00-0.880.000.00
Common Stock Issued115.06118.6074.350.3292.04
Other Financing Activities0.000.00-0.95-0.300.00
Net Cash from Financing Activities154.66130.1893.990.02131.77
Summary
Net Change in Cash-127.57153.29-99.673.18110.18
Cash at Beginning of Period224.9571.66171.33168.150.00
Cash at End of Period97.38-117.4971.66171.330.00
Free Cash Flow-84.59-117.49-49.543.16-21.59
Supplemental Disclosures
Interest Paid7.662.881.680.000.00